ArticleScientific reports2026
The association of TyG-BMI with MAFLD and liver fibrosis: a cross-sectional study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The early identification and risk stratification of metabolic-associated fatty liver disease (MAFLD) urgently require effective, non-invasive tools. This study aimed to comprehensively evaluate the association of the triglyceride-glucose-body mass index (TyG-BMI) with the risk of MAFLD prevalence and the degree of steatosis, and to further assess its potential as a biomarker for liver fibrosis. This cross-sectional study included 1,457 participants. Logistic regression were employed to assess the association between TyG-BMI and MAFLD risk, with diagnostic performance evaluated by ROC curve analysis. The relationships of TyG-BMI with MAFLD severity and liver stiffness measurement (LSM) were investigated. Individuals with MAFLD had a significantly higher TyG-BMI index than those without (242.02 ± 41.04 vs. 198.44 ± 33.99). After adjusting for confounders, each 1-unit increase in TyG-BMI was associated with a 3.4% increase in the risk of MAFLD (aOR = 1.034, 95% CI: 1.030-1.038). The AUC for TyG-BMI in diagnosing MAFLD was 0.806. This association was significantly modified by age, being stronger in younger individuals (≤ 60 years). Furthermore, trend tests indicated a significant increase in TyG-BMI levels with advancing degree of steatosis, and TyG-BMI was identified as an independent risk factor for the degree of steatosis (OR = 1.033). Additionally, the TyG-BMI index showed a significant positive correlation with LSM (Spearman's r = 0.255). A linear regression confirmed that TyG-BMI was an independent contributing factor to LSM (β = 0.011) after adjusting for age and sex. The TyG-BMI index is independently associated with the prevalence, severity, and fibrosis risk of MAFLD. As a simple, non-invasive index integrating routine metabolic parameters, it holds potential for initial screening and may provide ancillary information for fibrosis risk assessment in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.